Immuneering (NASDAQ:IMRX) Announces Quarterly Earnings Results

Immuneering (NASDAQ:IMRX) posted its quarterly earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.06), FiscalAI reports.

Immuneering Price Performance

Shares of Immuneering stock opened at $3.74 on Friday. Immuneering has a 1 year low of $3.38 and a 1 year high of $8.48. The firm has a market cap of $241.97 million, a PE ratio of -3.63 and a beta of 0.46. The company has a 50 day simple moving average of $4.28 and a two-hundred day simple moving average of $4.80.

Analyst Ratings Changes

A number of equities research analysts have commented on IMRX shares. Mizuho set a $11.00 price objective on Immuneering in a research note on Thursday. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a report on Monday, July 20th. UBS Group set a $14.00 price objective on Immuneering in a research note on Thursday, August 6th. Cantor Fitzgerald initiated coverage on Immuneering in a research note on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Immuneering in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immuneering has a consensus rating of “Moderate Buy” and a consensus price target of $15.67.

Hedge Funds Weigh In On Immuneering

Large investors have recently made changes to their positions in the business. VestGen Advisors LLC grew its stake in shares of Immuneering by 100.0% in the 3rd quarter. VestGen Advisors LLC now owns 20,002 shares of the company’s stock worth $82,000 after buying an additional 10,002 shares in the last quarter. Park Avenue Securities LLC bought a new position in Immuneering during the third quarter valued at $57,000. Vontobel Holding Ltd. bought a new stake in shares of Immuneering in the 3rd quarter worth about $71,000. WINTON GROUP Ltd bought a new stake in shares of Immuneering in the 2nd quarter worth about $86,000. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Immuneering during the 2nd quarter worth about $34,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.